Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Galmed Pharmaceuticals Ltd

GLMD
Current price
1.38 USD +0.02 USD (+1.47%)
Last closed 1.24 USD
ISIN IL0011313900
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 116 081 USD
Yield for 12 month -68.42 %
1Y
3Y
5Y
10Y
15Y
GLMD
21.11.2021 - 28.11.2021

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. Address: 16 Abba Hillel Road, Ramat Gan, Israel, 5250608

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

12.00 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

-31 000 USD

Current Quarter

Last Quarter

Key Figures GLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -6 195 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -22.34 %
PEG Ratio
Return On Equity TTM -49.77 %
Wall Street Target Price 12.00 USD
Revenue TTM
Book Value 9.81 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -8.08 USD
Diluted Eps TTM -8.08 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics GLMD

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History GLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:12
Payout Ratio
Last Split Date 30.08.2024

Stock Valuation GLMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 0.32
Price Book MRQ 0.19

Financials GLMD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GLMD

For 52 weeks

1.21 USD 15.10 USD
50 Day MA 1.97 USD
Shares Short Prior Month 48 498
200 Day MA 3.29 USD
Short Ratio 0.030
Shares Short 68 161
Short Percent 3.11 %